問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Cardiovascular Diseases

Division of Endocrinology

Division of General Internal Medicine

Division of Thoracic Surgery

Division of General Internal Medicine

更新時間：2025-12-17

林彥宏LIN, YEN-HUNG
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years 1 個月

Recruiting Trial

43Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林彥宏

List

73Cases

2019-03-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-03-01 - 2027-02-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Recruiting17Sites

2021-05-18 - 2023-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting5Sites

Terminated5Sites

2026-01-01 - 2031-09-18

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

2025-09-30 - 2032-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2023-12-15 - 2028-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-03-17 - 2024-05-02

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2023-09-01 - 2027-07-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2021-05-03 - 2021-06-11

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Terminated3Sites

2023-12-15 - 2028-06-30

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

  • Condition/Disease

    Transthyretin amyloid cardiomyopathy

  • Test Drug

    ALXN2220

Participate Sites
5Sites

Recruiting5Sites

1 3 4 5 6 7 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB